Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 449-454    DOI: 10.31083/j.ejgo.2020.03.5245
Original Research Previous articles | Next articles
Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?
Jingyuan Wang1, Xiaoping Li1, Danhua Shen2, Xiao Wang3, Zhiqi Wang1, *(), Jianliu Wang1
1Gynecology Department, Peking University People’s Hospital, Beijing, China
2Pathology Department, Peking University People’s Hospital, Beijing, China
3Peking University Sixth Hospital (Institute of Mental Health), National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China
Download:  PDF(334KB)  ( 301 ) Full text   ( 8 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose of Investigation: To determine if clear cell carcinoma (CCC) should be classified as a type I or type II carcinoma and provide guidance for clinical treatment. Material and Methods: This study included three groups of endometrial carcinomas: 92 cases of CCC were collected from 22 hospitals in China from January 2003 to November 2014, 272 cases of EMA were collected from Peking University People’s Hospital from February 2003 and July 2016, and 192 cases of USC were collected from 22 hospitals in China from February 2001 to December 2014. The 2009 FIGO staging system was used and information concerning clinicopathological features was collected. Results: The mean age in the CCC and USC groups was higher than that of the EMA group (p < 0.001). There was no significant difference in the FIGO Stage between the CCC and EMA groups (p = 0.158). There was no significant difference in the extent of myometrial invasion between the three groups (p = 0.064), but there was a significant difference in cervical involvement, adnexal metastasis, and lymph node metastasis (p = 0.017, p < 0.001, and p < 0.001). The patients in the CCC, EMA, and USC groups were followed up for an average of 105.6 ± 7.5 months, 135.0 ± 2.2 months, and 92.1 ± 4.4 months, respectively. Fourteen cases with CCC recurred, and 13 ended in death. There was no significant difference between the CCC and the EMA groups in recurrence and death rates (p = 0.035 > 0.0167, p = 0.018 > 0.0167, 0.0167 = 0.05/3), but the prognosis in the USC group was worse. Conclusions: CCC may follow an overlapping or a third pathway of carcinogenesis, rather than belong to the type II carcinogenesis. Therefore, if CCC should be classified as a type I or type II carcinoma is yet to be determined. Additional studies of the clinicopathological features underlying CCC will facilitate more elective management and avoid unnecessary or non-elective treatments.
Key words:  Clear-cell carcinoma      Clinicopathological features      Prognosis     
Submitted:  21 April 2019      Accepted:  25 June 2019      Published:  15 June 2020     
*Corresponding Author(s):  ZHIQI WANG     E-mail:  wangzqnet@sina.com

Cite this article: 

Jingyuan Wang, Xiaoping Li, Danhua Shen, Xiao Wang, Zhiqi Wang, Jianliu Wang. Clear-cell carcinoma of the endometrium:type I or type II endometrial carcinoma?. European Journal of Gynaecological Oncology, 2020, 41(3): 449-454.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5245     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/449

[1] Chados Nikolaos, Gregoriou Odysseas, Salakos Nicolaos, Kondis Agatha, Deligeoroglou Efthymios. The prognostic significance and immuno-expression of survivin, mutant p53 and bcl-2 in 92 cases of epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 517-522.
[2] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[3] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[4] T. Sakamoto, M. Miyamoto, T. Kono, H. Tsuada, H. Matsuura, T. Aoyama, M. Takano, K. Furuya. Endometrial dedifferentiated carcinoma: a case report. Pathological review at a single institution and systematic review of published literature[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 163-166.
[5] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[6] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[7] Y. Long, D.-s. Yao, Y.-s. Wei, J. Chen, X.-q. Ye. Perineural invasion in early-stage cervical cancer: detection and influence on prognosis[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 452-456.
[8] Lan Zhong, Feng Deng, Xingsheng Shu, Zhilan Peng. P53 overexpression predicts unfavorable prognosis of low risk endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 463-467.
[9] G. Huizhen, H. Jiaming, C. Haitian, Y. Juan, L. Tianyu, S. Hongwei, W. Zilian, K. Peiqi. Overexpression of CUL4B is a novel predictor of prognosis for endometrial adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 198-202.
[10] H. Cao, S. Yang, S. Xie, M. Xi. The association between p16INK4a and prognosis in endometrial carcinoma: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 311-317.
[11] Yu Feng, Yunchao Wang, Xia Zhao, Ying Mu, Shuzhen Lv, Yanping Li. Correlation between the intrinsic subtype and diagnostic methods of axillary lymph node metastasis in primary breast cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 921-925.
[12] K. Bodoor, A. Abu-sheikha, I. Matalka, H. Alzou’bi, O. Batiha, A. Abu-Awad, S.A. Jalboush, L. M. Fayyad, E. Qadiri, Y. Jarun, K. Albatayneh, Y. Haddad. Immunohistochemical analysis of heat shock proteins in triple negative breast cancer: HSP60 expression is a marker of poor prognosis[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 926-934.
[13] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[14] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
[15] Z.Y. Liu, L. Guo, G. Xiao, G.Y. Dong, Y.X. Zhang, H. Cheng, X.Y. Wang, C. Yang. Significance and expression of c-erBb-2, p53, and caspase-3 in breast cancer tissue in different age groups[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 430-432.
No Suggested Reading articles found!